JP2016508973A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508973A5
JP2016508973A5 JP2015548495A JP2015548495A JP2016508973A5 JP 2016508973 A5 JP2016508973 A5 JP 2016508973A5 JP 2015548495 A JP2015548495 A JP 2015548495A JP 2015548495 A JP2015548495 A JP 2015548495A JP 2016508973 A5 JP2016508973 A5 JP 2016508973A5
Authority
JP
Japan
Prior art keywords
her2
pharmaceutical
pharmaceutical formulation
preparation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548495A
Other languages
English (en)
Japanese (ja)
Other versions
JP6400595B2 (ja
JP2016508973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/077166 external-priority patent/WO2014096051A1/en
Publication of JP2016508973A publication Critical patent/JP2016508973A/ja
Publication of JP2016508973A5 publication Critical patent/JP2016508973A5/ja
Application granted granted Critical
Publication of JP6400595B2 publication Critical patent/JP6400595B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548495A 2012-12-21 2013-12-18 抗her2抗体製剤 Expired - Fee Related JP6400595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745293P 2012-12-21 2012-12-21
US61/745,293 2012-12-21
PCT/EP2013/077166 WO2014096051A1 (en) 2012-12-21 2013-12-18 Anti her2 antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018165536A Division JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Publications (3)

Publication Number Publication Date
JP2016508973A JP2016508973A (ja) 2016-03-24
JP2016508973A5 true JP2016508973A5 (https=) 2017-01-19
JP6400595B2 JP6400595B2 (ja) 2018-10-03

Family

ID=49779926

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015548495A Expired - Fee Related JP6400595B2 (ja) 2012-12-21 2013-12-18 抗her2抗体製剤
JP2018165536A Pending JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018165536A Pending JP2018199720A (ja) 2012-12-21 2018-09-05 抗her2抗体製剤

Country Status (15)

Country Link
US (2) US20150343058A1 (https=)
EP (1) EP2934582B1 (https=)
JP (2) JP6400595B2 (https=)
AU (1) AU2013360812B2 (https=)
BR (1) BR112015014853A2 (https=)
CA (1) CA2895869C (https=)
DK (1) DK2934582T3 (https=)
EA (1) EA201391729A1 (https=)
ES (1) ES2773103T3 (https=)
IL (1) IL239509A0 (https=)
MX (2) MX367748B (https=)
PL (1) PL2934582T3 (https=)
SG (1) SG11201504897YA (https=)
WO (1) WO2014096051A1 (https=)
ZA (1) ZA201504564B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
SG11202100653YA (en) * 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
SG11202109160UA (en) * 2019-03-22 2021-10-28 Somalogic Inc Reducing intersample analyte variability in complex biological matrices
JP2022538293A (ja) * 2019-06-28 2022-09-01 ジェネンテック, インコーポレイテッド 液体タンパク質製剤を安定化するための組成物及び方法
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
KR20220148200A (ko) 2020-02-28 2022-11-04 리제너론 파마슈티칼스 인코포레이티드 Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법
CN114504642B (zh) * 2020-11-17 2026-03-27 江苏奥赛康生物医药有限公司 一种含抗cldn18.2抗体的液体药物组合物
CN114762727A (zh) * 2021-01-15 2022-07-19 海正生物制药有限公司 一种稳定的帕妥珠单抗的药物组合物
CA3237877A1 (en) * 2021-11-12 2023-05-19 Aditya JARARE Novel formulation for drying of polymer dye conjugated antibodies
WO2023140807A1 (en) * 2022-01-19 2023-07-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of trastuzumab
TWI864690B (zh) * 2022-04-22 2024-12-01 台康生技股份有限公司 用於皮下投予之包含抗-her2抗體的藥學組合物
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68908175T2 (de) * 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 TNFα를 억제하는 안정적이고 가용성인 항체
BRPI0611901A2 (pt) * 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2016508973A5 (https=)
JP2014522843A5 (https=)
JP2020518599A5 (https=)
JP2016502504A5 (https=)
JP2016515511A5 (https=)
JP2013500947A5 (https=)
RU2013155695A (ru) Препараты антител против с-мет
JP2015534580A5 (https=)
JP2016515124A5 (https=)
RU2015144287A (ru) Составы конъюгата антитело против egfr-лекарственное средство
JP2014514346A5 (https=)
JP2017160208A5 (https=)
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
JP2019501204A5 (https=)
JP2016528251A5 (https=)
JP2016041733A5 (https=)
SI2691112T1 (en) STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
JP2017510661A5 (https=)
JP2015526440A5 (https=)
JP2012046518A5 (https=)
CN111356476A (zh) Lag-3抗体药物组合物及其用途
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
JP2013543505A5 (https=)
JP2018076350A5 (https=)
CR10244A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano